Predicting the risk for hospital-onset Clostridium difficile infection (HO-CDI) at the time of inpatient admission: HO-CDI risk score

Infect Control Hosp Epidemiol. 2015 Jun;36(6):695-701. doi: 10.1017/ice.2015.37. Epub 2015 Mar 10.

Abstract

Objective: To predict the likelihood of hospital-onset Clostridium difficile infection (HO-CDI) based on patient clinical presentations at admission

Design: Retrospective data analysis

Setting: Six US acute care hospitals

Patients: Adult inpatients

Methods: We used clinical data collected at the time of admission in electronic health record (EHR) systems to develop and validate a HO-CDI predictive model. The outcome measure was HO-CDI cases identified by a nonduplicate positive C. difficile toxin assay result with stool specimens collected >48 hours after inpatient admission. We fit a logistic regression model to predict the risk of HO-CDI. We validated the model using 1,000 bootstrap simulations.

Results: Among 78,080 adult admissions, 323 HO-CDI cases were identified (ie, a rate of 4.1 per 1,000 admissions). The logistic regression model yielded 14 independent predictors, including hospital community onset CDI pressure, patient age ≥65, previous healthcare exposures, CDI in previous admission, admission to the intensive care unit, albumin ≤3 g/dL, creatinine >2.0 mg/dL, bands >32%, platelets ≤150 or >420 109/L, and white blood cell count >11,000 mm3. The model had a c-statistic of 0.78 (95% confidence interval [CI], 0.76-0.81) with good calibration. Among 79% of patients with risk scores of 0-7, 19 HO-CDIs occurred per 10,000 admissions; for patients with risk scores >20, 623 HO-CDIs occurred per 10,000 admissions (P<.0001).

Conclusion: Using clinical parameters available at the time of admission, this HO-CDI model demonstrated good predictive ability, and it may have utility as an early risk identification tool for HO-CDI preventive interventions and outcome comparisons.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / therapeutic use
  • California / epidemiology
  • Clostridioides difficile / isolation & purification*
  • Cross Infection / prevention & control
  • Enterocolitis, Pseudomembranous* / diagnosis
  • Enterocolitis, Pseudomembranous* / epidemiology
  • Enterocolitis, Pseudomembranous* / etiology
  • Enterocolitis, Pseudomembranous* / prevention & control
  • Female
  • Hospitals / statistics & numerical data
  • Humans
  • Infection Control / methods*
  • Inpatients / statistics & numerical data
  • Male
  • Medication Therapy Management / statistics & numerical data
  • Middle Aged
  • Predictive Value of Tests
  • Research Design
  • Retrospective Studies
  • Risk Assessment / methods
  • Safety Management / methods

Substances

  • Anti-Bacterial Agents